MNV BLD
Alternative Names: Autologous cd34+ cells enriched with blood derived mitochondria; CD34+ cells enriched with MNV-BLD; MNV-101; MNV-BLD; MNV-BM-BLDLatest Information Update: 28 Apr 2025
At a glance
- Originator Minovia Therapeutics
- Class Haematopoietic stem cells therapies; Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase I/II VLCAD deficiency
- No development reported Mitochondrial disorders
Most Recent Events
- 28 Apr 2025 No recent reports of development identified for preclinical development in Mitochondrial disorders in USA (Parenteral)
- 03 Apr 2025 Efficacy data from a phase-I/II trial in VLCAD deficiency released by Minovia Therapeutics
- 21 Dec 2022 Efficacy data from a phase I/II trial in VLCAD deficiency released by Minovia Therapeutics